Cooperative Agreement NU2GGH002119

Federal Cooperative Agreement Summary The Centers for Disease Control and Prevention's Center for Global Health awarded a $595,000 Cooperative Agreement to the Ministerio De Salud (Ministry of Health) of Panama effective December 15, 2025, through September 29, 2030, under the Global AIDS program (CFDA 93.067). This award supports the scaling up of high-impact HIV prevention, testing, and treatment models in Panama as part of the President's Emergency Plan for AIDS Relief (PEPFAR). The...

This $2,777,976 Cooperative Agreement, awarded by the U.S. Agency for International Development (USAID) under the USAID Foreign Assistance for Programs Overseas (CFDA 98.001) program, aims to improve the response to HIV and ensure sustained epidemic control in targeted areas of the Democratic Republic of Congo (DRC). The primary awardee, Family Health International (FHI 360), will implement activities to decrease new HIV infections and reduce HIV-associated morbidity and mortality in the...

The Defense Health Agency awarded Jhpiego Corporation $933,052 under a Cooperative Agreement from October 1, 2021 to September 30, 2023 to support the Department of Defense HIV/AIDS Prevention Program. As part of this award, Jhpiego will provide reproductive, maternal, newborn, child, and adolescent health services, family health and nutrition activities, voluntary medical male circumcision and pre-exposure prophylaxis services, and health system performance improvement efforts to the Botswana...

Federal Cooperative Agreement Summary The National Center for HIV/AIDS, under the Centers for Disease Control and Prevention (CDC), awarded a $6.09 million cooperative agreement (CFDA 93.084: Prevention of Disease, Disability, and Death by Infectious Diseases) to the University of Colorado-Denver on September 30, 2025, for a three-year project period through September 29, 2028. The award, designated PS24-039, funds research to understand integrative care and support pathways to healthy aging for...

This Project Grant award of $160,000 from the Department of State Bureau of African Affairs supports efforts by Adpp Angola under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Programs (CFDA 19.029) to prevent mother-to-child transmission of HIV in Angola. Key deliverables include strengthening HIV care and treatment at health facilities, increasing community engagement, and building clinical laboratory and supply chain infrastructure from August 6, 2021 to September 30, 2021....

The U.S. Agency for International Development (USAID) awarded a $2,100,000 Cooperative Agreement under the Foreign Assistance for Programs Overseas (CFDA 98.001) grant program to the National Council of People Living with HIV/AIDS (NACOPHA) in Tanzania. The purpose of this 5-year project is to increase utilization of quality HIV prevention and treatment services by implementing community-led monitoring activities in close collaboration with the Government of Tanzania. The project will...

This federal Cooperative Agreement award, provided by the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention under the Global AIDS program (CFDA 93.067), will support the Cameroon Baptist Convention Health Board to develop, implement, and sustain high-quality comprehensive HIV cascade activities for children, adolescents, and adults in facility and community-based settings in Cameroon under the President's Emergency Plan for AIDS Relief (PEPFAR). The...

Cicatelli Associates, Inc. (CAI) received a $1.5 million Project Grant from the Health Resources and Services Administration (HRSA) HIV/AIDS Bureau under the HIV Emergency Relief Project Grants program (CFDA 93.914), effective April 1, 2026 through March 31, 2027. This award funds national training and technical assistance activities designed to strengthen the capacity of Ryan White HIV/AIDS Program (RHWAP) Parts A, B, C, D, and F to engage people with HIV who are out of care, particularly those...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...

This federal Project Grant award of $540,518.00 from the U.S. Department of Housing and Urban Development (HUD) under the Continuum of Care (CoC) Program (CFDA 14.267) supports Acadiana Concern For Aids Relief, Education And Support, Inc. in the delivery of housing assistance, healthcare, and supportive services to address homelessness, HIV/AIDS, and substance abuse in the Lafayette, LA area. As a recipient and sub-recipient of this CoC Program funding, Acadiana Concern provides rapid rehousing,...